This story summarizes the incremental benefits of two FDA-approved and relatively recent commercially available nuclear imaging tests designed to diagnosis prostate cancer and a rare neuroendocrine tumor earlier and more accurately. The imaging technologies in the piece have been the subject of recent corporate press releases and FDA announcements, and the article makes the most of the opportunity to fill in useful context about the comparative benefits of tweaked nuclear imaging capabilities vs other screening and diagnostic/prognostic testing.
The story focuses mostly on the prostate cancer test, and generally avoids hyperbole and does an overall good job of keeping expectations for the new tests in check. That said, the story would have been strengthened by having a comment from a front-line prostate cancer clinician or general oncologist, especially to weigh in on what the data shows. That’s because the story was lacking in quantitative data from studies demonstrating the tests’ accuracy, benefits and limits.
Earlier and better diagnostics for cancer is a holy grail in medicine, and any news about improvements and advances is likely to get attention from the sick and the worried well. Moreover, as with another gender-specific cancer — breast carcinoma — prostate cancer has been the subject and target of hot debates about the benefits and risks of screening, early detection, radical vs limited therapies, fear-mongering and statistical obfuscation.
Coverage of research about prostate cancer diagnostics and treatments has been at times as murky, contradictory, controversial and confusing as has been the case with breast cancer. No surprise then that men (and, as one book subtitle put it, “the women who love them,” ) are intensely interested in any news about technologies that can improve their chances of finding and surviving this disease. Journalists and news organizations should feel a special obligation, then, to cover purported advances in prostate cancer screening, prognosis and therapy, but to put substantial amounts of context in their stories.
There is no discussion about the actual or anticipated added costs of the new nuclear imaging tests compared to current diagnostic tests. Nor is there a sense of the overall costs of treatment.
The story offers good narrative explanations and opinions about the added value of the nuclear imaging tests, but no hard data to support the conclusions. The FDA approval processes certainly require data–both preclinical and clinical–and at least some of it should be cited.
The story makes claims about earlier detection of recurrence, but provides no data on how much more likely this is compared to following PSA or other currently available tests, and whether this earlier detection leads to better clinical outcomes. We already have good tests to evaluate spread to bone (advanced cancers) and lymph nodes. We would need data to show whether the new technology is more accurate–and cheaper than current tests.
The limitations and harms (from false positives, unnecessary biopsies, and unneeded surgery/radiation) from PSA screening and other current diagnostic procedures for prostate and other cancers are pretty well known. It’s unlikely that the newer nuclear imaging tests described in this article are without limitations and potential harms as well, including exposure to ionizing radiation, but there is no explicit/direct information about them. Also, finding low-risk cancers could pose psychological and physical harms from over diagnosis and over treatment.
This was a somewhat tough call, because the article is not, strictly speaking, describing the research behind the newly approved tests. But the article needed at least some indication about the strength or weakness of evidence for the use of these tests; who the best candidates are for the test; how widely they should or could be used; and their limitations.
Also, a big issue for prostate cancer screening is finding tests that better identify aggressive cancers–finding more cancers is not helpful given concerns about over diagnosis–especially low-risk cancers when PSA is <5. We found some of the discussion misleading: “Prostate-specific antigen, or PSA, is the common way to screen for the disease. But it isn’t entirely reliable because the PSA protein count also rises with age and disease of the prostate like inflammation, and it doesn’t help to determine the location of the tumor. That can be crucial in deciding on treatment.”
When PSA is elevated and/or the prostate exam is normal, cancer will be found through a biopsy performed with ultrasound (or more recently in some centers with MRI). Yes, PSA has false positives, but you can determine that only by performing biopsy–not an imaging study. Depending upon the PSA level, the digital rectal finding, and the biopsies, clinicians have a reasonable idea of whether the cancer is confined to the prostate–potentially curable–so the added value of the new imaging in this scenario is quite unclear.
The story quotes two sources independent of the companies’ representative. There do not appear to be conflicts of interest. The article needed more information about where the clinical trials were/are underway.
The article does a pretty decent job of talking about PSA screening, conventional (PET) nuclear imaging, and genetic testing, and ultimately defines the new nuclear tests as “complementary” by quoting an independent sources.
However, the story ideally also would have discussed alternatives for staging and determining recurrence, such as bone scans, CT scans and MRI.
The article provides no information about the availability of the new tests, either temporally or geographically.
The article describes how the new tests wed radioactive tracing materials with an amino acid (in the case of the prostate cancer) and other molecules, and sufficiently explains how the new tests differ from current nuclear images.
There were news releases issued recently by one of the companies involved in the commercialization of the tests, but the article does not appear to rely on them.
Systematic, Criteria-Driven
Take all the issues enmeshed in any cancer screening story and amplify it with the liquid biopsy issue. @AP's @CarlaKJohnson. did a solid job here. https://apnews.com/article/science-business-health-hodgkin-lymphoma-oregon-ca899bb9c4c7f1859d4e9ce16a1cf78d
Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like